menu search

PRAX / Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline
A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other preclinical drugs. Results from the phase 2b Essential1 study using PRAX-944 for treatment of patients with essential tremors expected 2nd half of 2022; preliminary results already released from phase 2a study. Read More
Posted: Jun 10 2022, 14:45
Author Name: Seeking Alpha
Views: 072963

PRAX News  

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

By GlobeNewsWire
August 28, 2023

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating gene more_horizontal

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

By GlobeNewsWire
June 2, 2023

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating gene more_horizontal

Praxis: Shaking The Dust Off Calcium Channel Blockers For Essential Tremor

By Seeking Alpha
March 3, 2023

Praxis: Shaking The Dust Off Calcium Channel Blockers For Essential Tremor

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the pot more_horizontal

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

By Seeking Alpha
June 10, 2022

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

A phase 2/3 trial failure in the MDD indication of PRAX-114 allows this biotech to shift focus over to PRAX-944 for Essential tremors and other precli more_horizontal

Praxis Precision Medicines, Inc. (PRAX) - CEO Marcio Souza on Q1 2022 Earnings Call Transcript

By Seeking Alpha
May 9, 2022

Praxis Precision Medicines, Inc. (PRAX) - CEO Marcio Souza on Q1 2022 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Marcio Souza – Presiden more_horizontal

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 28, 2022

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript more_horizontal

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 28, 2022

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript more_horizontal

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
February 28, 2022

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript

Praxis Precision Medicines, Inc. (PRAX) CEO Marcio Souza on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: